Abstract
We used reverse transcriptase–polymerase chain reaction analysis to study the effects of anti-rejection prophylaxis with an anti-interleukin (IL)-2 receptor (IL-2R) monoclonal antibody (BT563) on the allogeneic process by analyzing intragraft IL-2, IL-4, and IL-15 mRNA expression. Analysis showed an association between rejection and intragraft IL-2 mRNA and IL-4 mRNA transcription, whereas IL-15 was consitutively expressed: IL-2 62 % (8/13) during rejection versus 23 % (8/35) during immunological quiescence (P < 0.01); IL-4 69 % versus 23 % (P < 0.01). BT563 therapy influenced the intragraft mRNA expression of IL-2 and IL-4 but not of IL-15. In endomyocardial biopsies (EMB) showing rejection, mRNA expression of IL-2 was detectable in 40 % (2/5) during BT563 treatment versus 75 % (6/8) in the absence of BT563; for IL-4, 23 % versus 88 %, respectively. In contrast, IL-15 mRNA transcription was not affected. Quantitative analysis in rejection EMB showed comparable IL-15 mRNA levels during and after BT563 treatment. This study demonstrates that therapeutic intervention within the IL-2-dependent T-cell activation cascade does not completely prevent rejection. Other cytokines, such as IL-15, may participate in IL-2-independent rejections.
Similar content being viewed by others
Author information
Authors and Affiliations
About this article
Cite this article
Baan, C., Holweg, C., van Gelder, T. et al. Redundancy of the cytokine network in the development of rejection after clinical heart transplantation. Transpl Int 11 (Suppl 1), S512–S514 (1998). https://doi.org/10.1007/s001470050530
Issue Date:
DOI: https://doi.org/10.1007/s001470050530